Inhibrxの企業価値
Inhibrxの企業価値は何ですか。
Inhibrx, Inc.の企業価値は1.31B$です。
企業価値の定義は何ですか。
企業価値は、企業の総市場価値の尺度です。これは、負債、少数株主持分および優先株式から現金および現金同等物を差し引いた時価総額として計算されます。
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
NASDAQのセクタHealth Careにおける企業価値の企業と比べるInhibrx
Inhibrxは何をしますか。
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrxと類似の企業価値
- Godrej Agrovetの企業価値は1.31B$です。
- Savencia SAの企業価値は1.31B$です。
- Green Plains Incの企業価値は1.31B$です。
- Network18 Media & Investmentsの企業価値は1.31B$です。
- Welspun Indiaの企業価値は1.31B$です。
- GIC Housing Financeの企業価値は1.31B$です。
- Inhibrxの企業価値は1.31B$です。
- Magyar Telekom Telecommunications Plcの企業価値は1.31B$です。
- Desktop Metalの企業価値は1.31B$です。
- PTC Indiaの企業価値は1.32B$です。
- Score Media and Gamingの企業価値は1.32B$です。
- Ironwood Pharmaceuticals Incの企業価値は1.32B$です。
- Social Capital Hedosophia Holdiの企業価値は1.32B$です。